Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

Relief Announces That Collaboration Partner, Acer Therapeutics, was Issued U.S. Patent 11,202,767 Covering ACER-001 Methods of Use for Treatment of Urea Cycle Disorders and also Maple Syrup Urine Disease

GENEVA, SWITZERLAND/ ACCESSWIRE/ February 1, 2022/ RELIEF THERAPEUTICS Holding SA (SIX: RLF)(OTCQB: RLFTF)(OTCQB: RLFTY) (“Relief”), a biopharmaceutical …

Read More …